分化型甲状腺癌的遗传学现状
Actualities in genetics of differentiated thyroid cancer.
作者信息
Dobrescu R, Badiu C
机构信息
"C.I. Parhon" National Institute of Endocrinology - Research Laboratory, Bucharest, Romania.
"C.I. Parhon" National Institute of Endocrinology - Thyroid Related Disorders, Bucharest, Romania.
出版信息
Acta Endocrinol (Buchar). 2020 Jan-Mar;16(1):118-120. doi: 10.4183/aeb.2020.118.
Abstract
Genetics of cancer is a hot topic, an excellent example of translational medicine. Risk stratification, selection of cases for surgery in Bethesda categories 3 &4 FNAB are examples of the high impact of genetic evaluation in thyroid neoplasia.
摘要
癌症遗传学是一个热门话题，是转化医学的一个绝佳范例。风险分层、针对贝塞斯达分类3和4类细针穿刺活检（FNAB）病例选择手术，都是遗传学评估在甲状腺肿瘤中具有重大影响的实例。
相似文献
1
Actualities in genetics of differentiated thyroid cancer.
Acta Endocrinol (Buchar). 2020 Jan-Mar;16(1):118-120. doi: 10.4183/aeb.2020.118.
2
TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases.
Oncol Lett. 2018 Mar;15(3):2763-2770. doi: 10.3892/ol.2017.7675. Epub 2017 Dec 21.
3
The largest CAP-certified Chinese reference laboratory experience with the Bethesda system for reporting thyroid cytopathology: correlation with histologic and BRAF data.
J Am Soc Cytopathol. 2018 Jan-Feb;7(1):16-21. doi: 10.1016/j.jasc.2017.07.002. Epub 2017 Jul 26.
4
The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage.
Langenbecks Arch Surg. 2017 Mar;402(2):227-234. doi: 10.1007/s00423-017-1560-2. Epub 2017 Feb 3.
5
The rational use of fine needle aspiration biopsy (FNAB) in diagnosing thyroid nodules.
Minerva Endocrinol. 2006 Jun;31(2):159-72.
6
Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study.
J Clin Endocrinol Metab. 2012 Jul;97(7):2354-61. doi: 10.1210/jc.2011-3494. Epub 2012 Apr 24.
7
Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy.
Cancer Cytopathol. 2020 Feb;128(2):107-118. doi: 10.1002/cncy.22217. Epub 2019 Dec 10.
8
Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses.
Endocrine. 2017 Jul;57(1):98-107. doi: 10.1007/s12020-016-1105-4. Epub 2016 Sep 13.
9
Bethesda classification is a valuable guide for fine needle aspiration reports and highly predictive especially for diagnosing aggressive variants of papillary thyroid carcinoma.
Cytopathology. 2017 Aug;28(4):259-267. doi: 10.1111/cyt.12384. Epub 2016 Sep 25.
10
Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
Cancer. 2016 May 1;122(9):1370-9. doi: 10.1002/cncr.29934. Epub 2016 Mar 11.
引用本文的文献
1
PREDICTORS OF MULTIFOCAL PAPILLARY THYROID CANCER. DO THEY EXIST?
Acta Endocrinol (Buchar). 2022 Oct-Dec;18(4):424-428. doi: 10.4183/aeb.2022.424.
2
Comparison of surgical strategies in the treatment of low-risk differentiated thyroid cancer.
BMC Endocr Disord. 2023 Jan 26;23(1):23. doi: 10.1186/s12902-023-01276-8.
本文引用的文献
1
Genomic and Transcriptomic Characteristics According to Size of Papillary Thyroid Microcarcinoma.
Cancers (Basel). 2020 May 25;12(5):1345. doi: 10.3390/cancers12051345.
2
Obesity Is Associated with -Mutated Thyroid Cancer.
Thyroid. 2020 Oct;30(10):1518-1527. doi: 10.1089/thy.2019.0654. Epub 2020 May 4.
3
Molecular therapeutics for anaplastic thyroid cancer.
Semin Cancer Biol. 2020 Apr;61:23-29. doi: 10.1016/j.semcancer.2020.01.005. Epub 2020 Jan 25.
4
Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.
Endocrine. 2020 Jan;67(1):44-57. doi: 10.1007/s12020-019-02117-2. Epub 2019 Oct 26.
5
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.
Genes (Basel). 2019 Sep 13;10(9):709. doi: 10.3390/genes10090709.
6
Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.
Nat Commun. 2019 Jun 24;10(1):2764. doi: 10.1038/s41467-019-10680-5.
7
A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert!
Scand J Surg. 2020 Sep;109(3):187-192. doi: 10.1177/1457496919850434. Epub 2019 May 26.
8
TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
Eur J Cancer. 2019 Feb;108:41-49. doi: 10.1016/j.ejca.2018.12.003. Epub 2019 Jan 12.
9
Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population.
Pathol Oncol Res. 2020 Jan;26(1):347-354. doi: 10.1007/s12253-018-0497-2. Epub 2018 Oct 25.
10
Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.
Clin Cancer Res. 2018 Jul 1;24(13):3059-3068. doi: 10.1158/1078-0432.CCR-18-0373. Epub 2018 Apr 3.
Zotero 插件